Current Studies

The facts about participating in clinical research and our ongoing studies:

First and foremost your safety is our top priority. Participating in clinical research gives you access to the latest medical and scientific innovations in medicine as well as compensates the participant(s) for time and travel. Most importantly, you are advancing medical science by contributing to the development of vital new medicines and paving the way for these new medicines to reach the market.

Please let us know if you are interested in participating in a research study. Study participants receive medical care, lab tests, and study medication at no cost, and are compensated for their participation. Transportation can be provided.

For more information, please call: 954-366-0277.



To participate or refer a patient, please call 954-366-0277.

Clinical Coordinators: Jorge Riveros, IMG/CCRC • Adriana Bohorquez, IMG/MPH/CCRC • Rebecca Nembhard, CCRC

Biogen/EMERGE: Alzheimer’s Disease
A two-year study to evaluate a potential disease-modifying treatment given monthly by intravenous infusion on the effect of passive immunization on the progression of cognitive impairment/mild Alzheimer’s disease in patients who are 55 to 90 years old. Patients need study partner to attend some visits. (MMSE 26-30)

Lilly/DAYBREAK: Alzheimer’s Disease
An 18 Month study to evaluate an oral potential disease modifying therapy in patients 55-85 years old with Mild Alzheimer’s Disease with another 18 months on study drug (Open Label Extension). Patients need a study partner to attend some visits. (MMSE 20-26)

Allergan CGP-01: Migraine Prevention
A 12 month study evaluating the effectiveness of a daily oral medication for patients 18 to 65 who suffer from 4-14 migraine headaches with or without aura per month.

Novartis-Generation 2: Memory Loss
A long term study to evaluate the effectiveness of an oral potential disease modifying therapy in patients 60-80 years of age, first part of screening is genotyping for Alzheimer’s disease. Patients need a study partner to attend some visits. (MMSE 26-30)

Sunovion: Epilepsy
Open label study to evaluate safety and effectiveness Aptiom, as an add-on therapy or monotherapy for patients with uncontrolled partial onset seizures (POS).


To participate or refer a patient, please call 954-366-0277.

Clinical Coordinator: Lucy Vargas, MA, CRC

GSK – Captain: Asthma
A 52-week study comparing the efficacy, safety and tolerability of the fixed dose combination FF/UMEC/VI with the fixed dose dual combination of FF/VI, administered once-daily via a dry powder inhaler in subjects with inadequately controlled asthma- 18 and older

Pearl – 05: COPD
A 52-week study assessing the efficacy and safety of an inhaled medication in patients with moderate to severe COPD. For those 40-80 years of age.


To participate or refer a patient Call 954-475-8171, ext 146 (Fanny) or ext 138 (Adriana)

Clinical Coordinators: Fanny Gully, CRC and Adriana Araujo, CRC

Neurim Pharmaceuticals Ltd. – reCOGNITION: Mild Alzheimer’s disease
A 6 month placebo controlled, dose ranging study of piromelatine (5, 20, and 50 mg daily for 6 months) versus placebo to determine an effective dose based on efficacy (cognitive performance), safety and tolerability in patients with mild dementia due to AD. (MMSE 21-26)

Suven Life Sciences Ltd: Moderate Alzheimer’s disease
26-week long study to evaluate the safety and efficacy of SUVN-502 with donepezil and memantine for the treatment of moderate Alzheimer’s disease. (MMSE 12-20)

Eisai: Sleep disorder due to Alzheimer’s
An 11 week study to evaluate the Efficacy and Safety of Lemborexant in patients with Alzheimer’s having trouble staying awake during the day and sleeping through the night who are 60-90 years of age. (MMSE 15-26)

Roche – GRADUATE 2: Early Alzheimer’s Disease
A 24-month long study to evaluate a potential disease modifying therapy, monthly subcutaneous injections versus placebo in patients between 50 and 90 years old with memory loss or early Alzheimer’s disease with 24 month open label extension. (MMSE 20-30)

TOZ: Parkinson’s Disease
A 52 week open label study to evaluate an oral adjunctive therapy for Parkinson’s patients taking Levadopa and experiencing end of dose “wearing off. Patients 30-80 years of age.

Allergan-CGP: Migraine Prevention
A five month study evaluating the effectiveness of an oral daily medication in patients 18 to 75 who suffer from migraine headaches with or without aura.

Vertex: Small Fiber Neuropathy
A 6 week study evaluating the Efficacy and Safety of VX-150 in patients with pain caused by Small Fiber Neuropathy that are 18-80 years of age, with or without Diabetes.


To participate or refer a patient –Call 954-475-8171 Ext 134 (Michele)

Clinical Coordinator: Michelle Fistel, CCRC

Biogen-Affinity: Multiple Sclerosis
An 18-month placebo controlled monthly IV study to evaluate an add on therapy for Relapsing Remitting or Secondary Progressive MS (Primary or Secondary), must be 18-58 years of age, and be treated with one of the following DMTs for 6 months prior to baseline: Avonex, Plegridy, Betaseron, Rebif, Techfidera or Tysabri – Subjects will continue on their current therapy throughout the study.

Novartis-COMB: Multiple Sclerosis
A 2-year study for Multiple Sclerosis to evaluate an investigational monthly IV medication vs. Teriflunomide. Participants must be 18-55 years of age, with Relapsing Remitting or Secondary progressive MS.

Novartis-FLUENT: Multiple Sclerosis
A 1 year observational study for patients either taking Gilenya for 2 consecutive years or newly prescribed. Only blood draws and questionnaires required.